Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 10, 2010, Pages 1515-1522

  Verdier, Marie Clémence ^a,b   Bentué Ferrer, Danièle ^a,b   Tribut, Olivier ^a,b   Bellissant, Eric ^a,b  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

antifungal agents; liquid chromatography mass spectrometry (LC MS MS); therapeutic drug monitoring (TDM)

Indexed keywords

ACETONITRILE; FLUCONAZOLE; FORMIC ACID; HYDROXYITRACONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ACCURACY; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIQUID CHROMATOGRAPHY; MYCOSIS; PLASMA; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ANTIFUNGAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; TANDEM MASS SPECTROMETRY; TRIAZOLES;

EID: 77958175712     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.252     Document Type: Article

References (34)

1. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998;35:461-73.
2. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570-2.
3. Goa KL, Barradell LB. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial mycoses in immunocompromised patients. Drugs 1995;50:658-90.
4. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Töpelt K, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66.
5. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous highdose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996;61:1268-72.
6. Jordan MK, Polis MA, Kelly G, Narang PK, Masur H, Piscitelli SC. Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics. Antimicrob Agents Chemother 2000;44:2170-2.
7. Romero AJ, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002;71:226-34.
8. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following coadministration to healthy men. Curr Med Res Opin 2007;23:545-52.
9. Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007;27:825-34.
10. Nivoix Y, Levêque D, Herbrecht R, Koffel JC, Beretz L, Ubeaud-Sequier G. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008;47:779-92.
11. Nivoix Y, Ubeaud-Sequier G, Engel P, Levêque D, Herbrecht R. Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab 2009;10:395-409.
12. Brüggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009;48:1441-58.
13. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008;30:167-72.
14. Hope WW, Billaud EM, Lestnera J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008;21:580-6.
15. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008;61:17-25.
16. Pasqualotto AC, Shah M, Wynn R, Denning DW. Voriconazole plasma monitoring. Arch Dis Child 2008;93:578-81.
17. Imhof A, Schaer DJ, Schwarz U, Schanz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006;136:739-42.
18. Keevil BG, Newman S, Lockhart S, Howard SJ, Moore CB, Denning DW. Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2004;26:650-7.
19. Pereira R, Fidelis S, Vanunci ML, Oliveira CH, Mendes GD, Abib E, et al. Bioequivalence study of two fluconazole capsule formulations in healthy volunteers. Int J Clin Pharmacol Ther 2004;42:39-42.
20. Kim SS, Im HT, Kang IM, Lee HS, Lee HW, Cho SH, et al. An optimized analytical method of fluconazole in human plasma by high-performance liquid chromatography with ultraviolet detection and its application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci 2007;852:174-9.
21. Müller C, Arndt M, Queckenberg C, Cornely OA, Theisohn M. HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses 2006;49(Suppl 1):17-22.
22. Shen JX, Krishna G, Hayes RN. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J Pharm Biomed Anal 2007;43:228-36.
23. Störzinger D, Swoboda S, Lichtenstern C, Müller C, Weigand MA, Hoppe-Tichy T. Development and validation of a highperformance liquid chromatography assay for posaconazole utilizing solid-phase extraction. Clin Chem Lab Med 2008;46:1747-51.
24. Vogeser M, Rieger C, Ostermann H, Spöhrer U. A routine method for the quantification of the novel antimycotic drug posaconazole in plasma using liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 2009;47:579-84.
25. Bharathi DV, Hotha KK, Sagar PV, Kumar SS, Reddy PR, Naidu A, et al. Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of itraconazole and hydroxy-itraconazole in human plasma: application to a bioequivalence study. J Chromatogr B 2008;868:70-6.
26. Vogeser M, Spöhrer U, Schiel X. Determination of itraconazole and hydroxyitraconazole in plasma by use of liquid chromatography-tandem mass spectrometry with on-line solid-phase extraction. Clin Chem Lab Med 2003;41:915-20.
27. Vogeser M, Schiel X, Spöhrer U. Quantification of voriconazole in plasma by liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 2005;43:730-4.
28. Chhun S, Rey E, Tran A, Lortholary O, Pons G, Jullien V. Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007;852:223-8.
29. Gordien JB, Pigneux A, Vigouroux S, Tabrizi R, Accoceberry I, Bernadoua JM, et al. Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection. J Pharm Biomed Anal 2009;50:932-8.
30. Guidance for Industry, Bioanalytical Method Validation. U. S. Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM), 2001. http://www.fda.gov/CDER/GUIDANCE/4252fnl.pdf.
31. Causon R. Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. J Chromatogr B 1997;689:175-80.
32. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003;75:3019-30.
33. Van Eeckhaut A, Lanckmans K, Sarre S, Smolders I, Michotte Y. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects. J Chromatogr B 2009;877:2198-207.
34. Assurance de Qualité des Laboratoires d'Analyses Médicales (ASQUALAB). http://www.asqualab.com/.